Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno(National Defense Medical College), Masao Tanaka(Kyoto University), Shinichi Egawa(Tohoku University), Narikazu Boku(Tokyo Medical University), Ann‐Lii Cheng(National Taiwan University), Masafumi Ikeda(National Cancer Center Hospital East), Tatsuya Ioka(National Cancer Center Hospital East), Hiroaki Yanagimoto(National Cancer Center Hospital East), Masayuki Sho(Nara Medical University), T Shimamura(National Cancer Center Hospital East), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Junji Furuse(Kanagawa Prefectural Hospital Organization), Kazuhiro Mizumoto(National Cancer Center Hospital East), Masayuki Kitano(Wakayama Medical University), Taketo Yamaguchi(National Cancer Center Hospital East), Takuji Okusaka(National Cancer Centre Japan), Kenji Yamao(Aichi Cancer Center), Yasuo Ohashi(Chuo University), Hideo Baba(Kaketsuken (Japan)), Atsushi Satō(National Cancer Center Hospital East), Takashi Hatori(National Cancer Center Hospital East), Shinichi Ohkawa(National Cancer Center Hospital East), Kazuya Sugimori(National Cancer Center Hospital East), Akihiro Funakoshi(National Cancer Center Hospital East), Akira Fukutomi(Shizuoka Cancer Center)
Cited by 632
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k